Business Wire

SPIRIT-SEMICONDUCTOR

Share
Spirit Semiconductor Expanding Theale Headquarters and Opening Second Office in Leeds, UK

Spirit Semiconductor, an innovator in high-performance radio frequency solutions, today announced it will be moving to a new headquarters in Theale, U.K. and will be opening a new satellite office in Leeds, U.K. to tap into the strong radio frequency (RF) monolithic microwave integrated circuit (MMIC) and filter engineering talent in Northern England. The expansion comes on the heels of swift customer adoption and deployment of Spirit Semiconductor’s technology for 5G massive multiple-input and multiple-output (mMIMO) and small cell base stations.

Since the company’s inception in 2020, it has experienced rapid growth, developing a core team of 15 people in less than one year. Located in one of the U.K.’s technology hotbeds, the new office is five times larger than current Spirit headquarters, boasting 9,000 square feet of office space. The new Leeds office will support the company’s plans to expand its product portfolio and enter into other high growth markets.

“When Spirit Semiconductor was founded last year, we were solely focused on creating cutting edge radio frequency products for 5G mMIMO. Currently, our products are being evaluated by customers but the feedback we have received so far has been hugely positive and really provides us with the encouragement we need to branch out into other markets,” said Mark Moffat, managing director of Spirit Semiconductor. “At this rate, we are targeting 65% growth in 2021. This is only the beginning for our company, and I could not be more excited to see what the next year brings by way of innovation and expansion.”

“Massive MIMO architectures change the fundamental building blocks of the RF chain dramatically,” commented Joe Madden, chief analyst at Mobile Experts. “We are experiencing very rapid market growth for some RF components as the base station design adapts to 32T and 64T variations of massive MIMO, with tight performance requirements for RFICs to support a wide range of applications.”

Spirit Semiconductor is looking for the semiconductor industry’s top talent. The company is currently hiring for several positions: principal filter design engineer, principal MMIC design engineer, senior MMIC design engineer and senior analog IC design engineer. For additional information, contact Luke Ord at IC Resources, luke.ord@ic-resources.com , +44 118 907 3070.

“IC Resources is excited to be helping Spirit Semiconductor to identify the right talent to fuel its impressive growth,” commented Kathy Campling, client services director at IC Resources. “Spirit’s strong business plan, exciting product roadmap and generous benefits package are an attractive proposition to potential employees.”

About Spirit Semiconductor Ltd.

Spirit Semiconductor Ltd. is a United Kingdom based company, founded by experts in the radio frequency (RF) semiconductor industry. We are focused on developing high-performance RF products to support the rapid roll out of 5G massive MIMO (mMIMO), small cell base stations and other markets requiring high performance solutions. At Spirit Semiconductor our approach is intelligent innovation, fast implementation and strong team collaboration. We are an aggressive, fast-moving group that is focused on developing compelling products that meet our customers’ needs and timescales, while maintaining a strong team ethic and collaborative spirit. We believe in developing a balanced team that has all levels of experience and fostering an environment where everyone has the opportunity to learn and grow. To learn more, visit www.spiritsemiconductor.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye